|
KMID : 0939920190510041578
|
|
대한암학회지
2019 Volume.51 No. 4 p.1578 ~ p.1588
|
|
|
Temsirolimus in Asian Metastatic/Recurrent Non-clear Cell Renal Carcinoma
|
|
Lee Jii-Bum
Park Hyung-Soon
Park Se-Jung
Lee Hyo-Jin
Kwon Kyung-A
Choi Young-Jin
Kim Yu-Jung
Nam Chung-Mo
Cho Nam-Hoon
Kang Beo-Deul
Chung Hyun-Cheol
Rha Sun-Young
|
|
|
Abstract
|
|
|
Purpose: Temsirolimus is effective in the treatment for metastatic non-clear cell renal cell carcinoma (nccRCC) with poor prognosis. We aim to investigate the efficacy and tolerability of temsirolimus in treatment of naive Asian patients with metastatic/recurrent nccRCC.
Materials and Methods: From January 2008 to July 2017, data of treatment-naive, metastatic/recurrent nccRCC patients, who were treated with temsirolimus according to the standard protocol, were collected. The primary end-point was progression-free survival (PFS). Secondary end points were overall survival (OS), objective response rate (ORR), and tolerability of temsirolimus.
Results: Forty-four metastatic/recurrent nccRCC patients, 10 from prospective and 34 from retrospective groups, were enrolled; 24 patients (54%) were papillary type, and other histology subtypes included 11 chromophobes (25%), two collecting ducts (5%), one Xp11.2 translocation (2%), and six others (14%). The median PFS and OS were 7.6 months and 17.6 months, res-pectively. ORR was 11% and disease control rate was 83%. Patients with prior nephrectomy had longer PFS (hazard ratio [HR], 0.16; 95% confidence interval [CI], 0.06 to 0.42; p < 0.001) and OS (HR, 0.15; 95% CI, 0.05 to 0.45; p < 0.001). Compared to favorable/intermediate prognosis group, poor prognosis group had shorter median PFS (4.7 months vs. 7.6 months [HR, 2.91; 95% CI, 1.39 to 6.12; p=0.005]) and median OS (9.2 months vs. 17.6 months [HR, 2.84; 95% CI, 1.23 to 6.56; p=0.015]).
Conclusion: Temsirolimus not only benefits poor-risk nccRCC patients, but it is also effective in favorable or intermediate-risk group in Asians. Temsirolimus was well-tolerated with manageable adverse events.
|
|
|
KEYWORD
|
|
|
Temsirolimus, First-line, Asian, Renal cell carcinoma, Efficacy, Tolerability
|
|
|
FullTexts / Linksout information
|
|
 
|
|
|
Listed journal information
|
|
    
|
|